Posttraumatic Stress Disorder (PTSD)

Evaluation of the Efficacy of the CRF1 Antagonist GSK561679 in Women with Post-Traumatic Stress Disorder

This study will test the hypothesis of whether an antagonist at the corticotropin releasing factor type 1 receptor (i.e. GSK561679) is superior to placebo in reducing symptoms of PTSD. The study is being conducted at 2 sites in the United States: a site at Emory University, and one at Mount Sinai School of Medicine. About 150 women outpatients aged 21 to 65 who currently suffer from PTSD will be enrolled. Study participation could last for up to about 12 weeks.

Organization: 
Emory University School of Medicine, Atlanta, GA and Mount Sinai School of Medicine, New York, NY
Principal Investigator: 
Barbara Rothbaum PhD & Boadie Dunlop, MD (Emory University) and Dan Iosifescu, MD (Mount Sinai School of Medicine)
Eligibility Criteria: 

1. Women  between the ages of 21 and 65
2. Fulfills DSM-IV criteria for a primary diagnosis of Post-traumatic stress disorder (PTSD)
3. Duration of PTSD is at least 3 months
4. Able to read and speak English
5. For women of reproductive age, must use of an effective birth control method or abstinence for the duration
6. Clinician-administered PTSD Scale score at Screening and Randomization visits of ≥ 50 on the CAPS
7. For women who have a history of peptic ulcer disease (PUD) with known etiology, evidence of effective treatment was provided with full eradication of ulcers and symptoms must be provided.
                                                                        

Exclusion Criteria: 

1.    Lifetime diagnosis of a psychotic disorder (including schizophrenia), disorder, bipolar disorder, or obsessive compulsive disorder.
2.   Current or past month participation in another clinical trial in which she is or will be exposed to an investigational or non-investigational drug or device.
3.   A current significant unstable medical illness or organic brain impairment, including stroke, CNS tumor, demyelinating disease, cardiac, pulmonary, gastrointestinal, renal or hepatic impairment that would likely interfere with the action, absorption, distribution, metabolism, or excretion of GSK561679.
4.    Patients who in the investigator’s judgment pose a current suicidal or homicidal risk
5.   Substance abuse or dependence within the past 90 days, or testing positive for illegal substances.
6.  Current diagnosis of anorexia or bulimia nervosa.
7.  A documented history of hepato-biliary disease including evidence of current hepatitis infection, or clinically significant hepatic enzyme elevation including any one of the following enzymes greater than 1.5 times the upper limit of normal (ULN) value (ALT, AST, ALP, total or direct bil > 1.5 x ULN, unless consistent with presumed or diagnosed Gilbert’s disease
8.    Taking systemic corticosteroids within 2 weeks of the Randomization Visit
9.    Treatment with any other psychoactive medication within 2 weeks of Screening visit, including psychoactive herbal or nutritional treatment.
10.  Likely need for more than 2 weeks of regular NSAID use or any use of aspirin.
11.  Taking any medication with with a narrow therapeutic index, that are metabolized via the cytochrome P450 3A4 or 2C9 pathway (e.g. warfarin), or transported via OATP1B1 or P-gp, within 2 weeks (or 5 half-lives, whichever is longer) prior to the Randomization Visit.
12.  Taking any products that are potent inducers or inhibitors of the cytochrome P450 3A4 pathway for 2 weeks (or 5 half lives, whichever is longer) prior to the Randomization Visit.
13.  Stool positive for occult blood.
14.  Pregnancy or lactation*
15.  Participants who, in the opinion of the investigator, would be noncompliant with the visit schedule or study procedures (e.g. illiteracy, planned vacations, or planned hospitalizations during the study).
16.  Previous treatment with CRF1 receptor antagonist
17.  Any laboratory abnormality that in the investigator’s judgment is considered to be clinically significant (e.g. blood pressure, ECG, TSH, LFT, etc.)
18.  Patients who are receiving exposure-based psychotherapy that targets PTSD symptoms
19.  Current or planned litigation or other actions related to secondary gain regarding the traumatic event

Contact: 
Christopher Vaughan, 404-778-6663, studies@emoryclinicaltrials.com
Location: 
Atlanta, GA
State: 
Georgia
Study End Date: 
Wed, 2013-05-01

Treating PTSD and Traumatic Brain Injury

Richard A. Bryant, PhD
Director, Traumatic Stress Clinic
Scientia Professor of Psychology, University of New South Wales
Sydney, Australia

Dr. Bryant talks about  the intersection of traumatic brain injury (TBI) and PTSD, including treatment and how therapy needs to be adapted for TBI survivors.

Listen

Anxiety Disorders (Pediatric) Research Study

This study uses functional magnetic resonance imaging (fMRI) to learn how the brain functions in adolescents receiving fluoxetine (Prozac) or cognitive behavioral therapy (CBT) for anxiety or depression in children/adolescents. All participants will receive interviews to assess how they are doing in general, including his or her general mood, degree of nervousness and behavior. Each participant and one of his or her parents will be interviewed separately and together.

Organization: 
NIMH
Principal Investigator: 
Daniel S. Pine, MD; 301-594-9960, Daniel.Pine@nih.hhs.gov
Eligibility Criteria: 

JUVENILE SUBJECTS

Age: 8 to 17

Consent: Can give consent/assent. (Parents will provide consent; minors will provide assent.)

IQ: All subjects will have IQ greater than 70 (Assessment relies on WASI)

SUBJECTS WITH AN ANXIETY DISORDER

Diagnosis: Current Diagnosis of Social Phobia, Separation Anxiety, or Generalized Anxiety Disorder (Based on K-SADS)

Symptom Severity: Score greater than 9 on PARS (This score was used to enroll subjects in previous trial demonstrating efficacy of an SSRI in pediatric anxiety.)

Clinical Impairment: CGAS less than 60

SUBJECTS WITH A MOOD DISORDER

Diagnosis: Current Diagnosis of Major Depression (Based on K-SADS (juveniles) or SCID (adults))

Clinical Impairment: CGAS less than 60 (juveniles) GAS less than 70 (adults)

Symptom Severity: CDRS Score greater than 39 (juveniles) (This score was used to enroll subjects in previous trials demonstrating efficacy of an SSRI in pediatric depression.)

ADULT SUBJECTS

Age: 20-40

Consent: Can give consent/assent.

IQ: All subjects will have IQ greater than 70. Assessment relies on WASI.

Exclusion Criteria: 

ALL SUBJECTS:

Any serious medical condition or condition that interferes with fMRI scanning, and for patients electing medication, any condition that increases risk of SSRI treatment. All patients will have complete physical examination. Healthy volunteer participants will be medication-free and have no current serious medical conditions, based on a review of their medical history.

Pregnancy

Current use of any psychoactive substance; current suicidal ideation; current diagnosis of attention deficit hyperactivity disorder (ADHD) of sufficient severity to require pharmacotherapy. These factors could complicate treatment with an SSRI. No subject on medication will be accepted into the trial. Subjects will not be taken off of medications to enter the trial.

Current diagnoses: Tourette's, OCD, posttraumatic distress disorder, conduct disorder. These factors may be effected by SSRI treatment, influencing ability to detect effects on anxiety/depression

Past or current history of mania, psychosis, or pervasive developmental disorder. These factors may be effected by SSRI treatment, influencing ability to detect effects on anxiety/depression

Recent use of an SSRI: All subjects must have been free of any SSRI use for at least one month (fluoxetine six months) and must not have been treated with an SSRI for their current depressive episode. This is designed to exclude subjects who have failed a trial of an SSRI for their current episode of major depression.

HEALTHY ADULT SUBJECTS

Any current psychiatric diagnosis. Assessment relies on SCID.

SUBJECTS WITH AN ANXIETY DISORDER

Current Major Depressive Disorder

Contact: 
Allison M. Detloff, 301-451-6817, detloffa@mail.nih.gov
Location: 
Bethesda
State: 
Maryland
Study End Date: 
Tue, 2013-12-31

Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD)

The primary aim of this study is to compare the effectiveness of two lifestyle interventions for improving the outcome of prolonged exposure therapy (PE) for PTSD. Eligible participants will receive free PE for 12 weeks and participate in either a wellness or exercise program (determined by a flip of a coin).

 

Organization: 
Southern Methodist University
Principal Investigator: 
Mark B. Powers, PhD
Eligibility Criteria: 
  • You have PTSD
  • You are between the age of 18 and 54 if female or between ages 18 and 44 if male.
  • You have written physician approval/medical clearance to participate in an exercise protocol.
  • Are currently taking no psychotropic medications or are able and willing to discontinue these medications prior to the first PE session.
Exclusion Criteria: 
  • You are currently participating in a structured exercise program
  • You have severe depression
  • You have any history of bipolar disorder, psychotic disorder, or obsessive compulsive disorder;
  • You have a diagnosis of eating disorder, or substance abuse or dependence (excluding nicotine) within the past six months
  • You have any history of a suicide attempt, or are at significant risk of self-harm or harm to others
  • You have ever been diagnosed with organic brain syndrome, mental retardation, or other cognitive dysfunction
Contact: 
Mark B Powers, PhD, 214-768-7848, trauma@smu.edu; Stephanie Burns, 214-768-4310, anxiety@smu.edu
Location: 
Dallas, TX
State: 
Texas
“I'm no longer at the mercy of my PTSD, and I would not be here today had I not had the proper diagnosis and treatment. It's never too late to seek help.”

My Story of Survival: Battling PTSD

It is a continuous challenge living with posttraumatic stress disorder (PTSD), and I've suffered from it for most of my life. I can look back now and gently laugh at all the people who thought I had the perfect life. I was young, beautiful, and talented, but unbeknownst to them, I was terrorized by an undiagnosed debilitating mental illness.

Read

Integrated treatment for veterans with PTSD and chronic pain

Researchers have developed a 12-session treatment for veterans suffering from comorbid chronic pain and PTSD. The results of a pilot study found that several soldiers no longer met diagnostic criteria for PTSD and had reduced symptoms of chronic pain.

PTSD may raise post-surgery death risk

Veterans with posttraumatic stress disorder face an increased risk for dying after surgery (non-cardiac, non-emergency), even if the surgery is performed years after they have completed their service, according to researchers at the San Francisco VA Medical Center. One year after surgery, the death rate among men with PTSD was 25 percent higher than for those without PTSD, highlighting the need to consider treatments to help reduce risk in the veteran PTSD population.

Screening for Posttraumatic Stress Disorder (PTSD)

If you suspect that you might suffer from PTSD, answer the questions below, print out the results and share them with your health care professional.

Are you troubled by the following?

“Thanks to a very loving and understanding partner, I was able to work through more of the anxiety I felt.”

Redefining My Life

My struggles with emotional and mental problems began at age 12, when I experienced my first nervous breakdown. At age 20 I was diagnosed with major depression. By the time I was 30 that diagnosis had changed to chronic major depression with generalized anxiety disorder (GAD). Later, ADHD and obsessive-compulsive disorder (OCD) were added to my diagnoses. At age 40, and after three suicide attempts within two years, my therapist began to suspect that I suffered from bipolar disorder.

Read

Contact ADAA

8701 Georgia Ave. #412
Silver Spring, MD 20910

240.485.1001

Contact ADAA

Request Publications

FacebookTwitterRSS

Syndicate content RSS

 

ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, OCD, PTSD, depression, and related disorders and to improving the lives of all people who suffer from them.